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Objective: Preeclampsia is a major cause of mortality in pregnant women but the underlying mechanism
remains unclear to date. In this study, we attempted to identify candidate proteins that might be
associated with preeclampsia in pregnant women by means of proteomics tools.
Materials and methods: Differentially expressed proteins in serum samples obtained from pregnant
women with severe preeclampsia (n ¼ 8) and control participants (n ¼ 8) were identiﬁed using two-
dimensional gel electrophoresis (2-DE) followed by peptide mass ﬁngerprinting using matrix-assisted
laser desorption/ionization time-of-ﬂight mass spectrometry (MALDI-TOF/MS). Additional serum sam-
ples from 50 normal and 41 pregnant women with severe preeclampsia were analyzed by immunoassay
for validation.
Results: Ten protein spots were found to be upregulated signiﬁcantly in women with severe pre-
eclampsia. These protein spots had the peptide mass ﬁngerprints matched to a1-antitrypsin, a1-
microglobulin, clusterin, and haptoglobin. Immunoassays in an independent series of serum samples
showed that serum a1-antitrypsin, a1-microglobulin, and clusterin levels of severe preeclampsia pa-
tients (n ¼ 41) were signiﬁcantly higher than those in the normal participants (n ¼ 50; a1-antitrypsin
295.95 ± 50.94 mg/dL vs. 259.31 ± 33.90 mg/dL, p ¼ 0.02; a1-microglobulin 0.029 ± 0.004 mg/mL vs.
0.020 ± 0.004 mg/mL, p < 0.0001; clusterin 77.6 ± 16.15 mg/dL vs. 67.6 ± 15.87 mg/dL, p < 0.05).
Conclusion: Identiﬁcation of these proteins by proteomics analysis enables further understanding of the
pathophysiology of preeclampsia. Further studies are warranted to investigate the role of these bio-
markers in prediction of this disease.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
With an incidence of approximately 5% around the world, pre-
eclampsia is a major cause of mortality in pregnant women [1]. The
incidence of preeclampsia in Taiwan is reported to be 2.03%;and Gynecology, Kaohsiung
Sung District, Kaohsiung City,
bstetrics & Gynecology. Publishednevertheless, it contributes to 23.7% of perinatal maternal death [2].
Unfortunately, the cause of preeclampsia remains unclear to date.
Preeclampsia is associated with abnormal placentation, reduced
placental perfusion, and systemic vasospasm. Hormone factors as
well as vascular and hemostatic hyper-reactivities involving the
renineangiotensin system, eicosanoids, and platelets have all been
implicated [3].
The pathogenic mechanisms behind preeclampsia are totally
different from other hypertensive disorders. Biochemical markers
related to angiogenesis are generally chosen because theby Elsevier Taiwan LLC. All rights reserved.
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essential for normal placental development [4]. A number of
potentially useful biochemical markers of angiogenesis such as
vascular endothelial growth factor, placental growth factor, and
endoglin have been implicated in preeclampsia [5,6]. Inﬂammatory
cytokines [tumor necrosis factor-a (TNF-a), interleukin, etc.] are
known to be potent activators of the vascular endothelium and
have been shown to be produced by trophoblasts and Hofbauer
cells in the placenta [7]. Rinehart et al [8] reported that expression
of the placental cytokines TNF-a, interleukin 1b, and interleukin 10
were increased in pregnant women with preeclampsia. To identify
the patients at risk of developing severe preeclampsia at an early
stage would be of great value to prevent the condition, to observe it
closely in advance, and to offer the patients appropriate treatment.
However, there are only a few tests available to screen for pre-
eclampsia at the present time.
Comparative proteome analysis is a new technology to identify
speciﬁc proteins or peptides which would be candidates of interest
involving some of the diseases [9]. Novel proteins associated with
preeclampsia could provide clues to the pathophysiology of the
disorder and might also be used as speciﬁc markers for early
detection and treatment. The goal of the present study was to
identify candidate proteins that might be associated with pre-
eclampsia in pregnant women by means of proteomics tools.
Materials and methods
Sample collection and preparation
The study was designed as a case-control study. After the Insti-
tute Review Board approved the study, 58 pregnant women with
severe preeclampsia were identiﬁed at our medical center between
August 2005 and July 2006. As case controls, we enrolled another 58
healthy gestational age-matched control individuals in a manner of
one healthy pregnant woman being selected to the study when a
severe preeclampsia case was collected. The criteria used for the
diagnosis of preeclampsia were established in accordance with the
guidelines of the American College of Obstetricians and Gynecolo-
gists (ACOG). Severe preeclampsia was deﬁned as blood pressure
160/110 mmHg after the 20th week of gestation and proteinuria
2.0 g/24 h or 3 by dipstick, serum creatinine >1.2 mg/dL, platelet
count <100,000/mm3, elevated alanine transaminase (ALT) or
aspartate aminotransferase (AST) and persistent headache, epigas-
tric pain, or other cerebral or visual disturbance. None of thewomen
had uterine contraction, rupture of membrane, vaginal bleeding or
were in labor. We initially identiﬁed 58 women with severe pre-
eclampsia, but nine were excludeddfour because of pre-existing
hypertension or pre-existing proteinuria and ﬁve for preterm la-
bor or rupture of membrane at initial presentation. Samples of the
corresponding nine healthy pregnancies were already analyzed and
maintained in the control group. As a result, a total of 107 women
were included and 6-mL peripheral blood samples were obtained
from every patient. In the ﬁrst part of our study, blood samples of
eight womenwith severe preeclampsia and eight healthy pregnant
womenwere collected as a screening group for proteomic analysis.
In the second part of our study, blood samples from 41womenwith
severe preeclampsia and 50 healthy pregnant women were
collected as a validation group for serum immunoassay. Blood
sampleswere centrifugedat 3000 rpm for 15minutes and the serum
samples were stored in microtubes at 80C until assayed.
Two-dimensional gel electrophoresis and image analysis
For two-dimensional gel electrophoresis (2-DE), 200 mg of
serum sample was added to 250 mL of rehydration solution tobecome a test solution. Rehydration solution consisted of 8M urea,
2% 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfo
nate (CHAPS), 0.5% immobilized pH gradient (IPG) buffer (Amer-
sham Biosciences, Piscataway, NJ, USA), 40mM dithiothreitol (DTT),
and 0.002% bromophenol blue as tracking dye. First-dimensional
isoelectric focusing (IEF) was carried out using an IPGphor system
(Amersham Biosciences). Test solution (250 mL including the sam-
ple) was applied to each gel strip (Immobiline DryStrip gels 13 cm,
pH 4.0e7.0; Amersham Biosciences). IEF conditions were 16 hours
at 30 V, then 1 hour at 500 V, 1 hour at 1000 V, and 4 hours at
8000 V. Prior to the second-dimension separation, gels were
equilibrated. The sodium dodecyl sulfate (SDS) equilibration buffer
contained 50mM Tris-HCl, 6M urea, 30.45% glycerol, 2% w/v SDS,
and 0.002% bromophenol blue as tracking dye. First equilibration
was performed by adding 100mg DTT to 10 mL of SDS equilibration
buffer for 15 minutes. Then, 250 mg iodoacetamide was added to
10 mL of SDS equilibration buffer for 15 minutes to achieve second
equilibration. Protein separation by size in the 2-DE was performed
in 1.5-mm-thick linear 10% polyacrylamide gels (18 cm  16 cm) at
10 mA/gel for 20 minutes, and then at 25 mA/gel until the tracking
dye reached the anode. In all experiments, the 2-DE was performed
immediately after IEF. After SDS polyacrylamide gel electropho-
resis, the proteins were detected with silver staining. The gel was
scanned using a GS710 imaging densitometer (Amersham Bio-
sciences) and analyzed using Image Master 5.0 software (Amer-
sham Biosciences). Image Master 5.0 software was used to locate
and measure protein spots and compare spots between gels. Spot
measurements were normalized by expressing the optical density
of a spot as a percentage of the sum of the optical densities for all
spots detected on the gel.
In-gel proteolytic digestion
The spotswere excised from gels using a pipet tip of large oriﬁce,
sliced into 0.6-mL micro centrifuge tubes and then washed three
times with MilliQ water. The gel pieces were then destained with
30mM potassium ferricyanide and 100mM sodium thiosulfate and
washed three times with 200 mL of a solution containing 50mM
ammonium bicarbonate/100% acetonitrile (3:2). The gel pieces
were then shrunk in 100% acetonitrile followed by drying under
vacuum in an Eppendorf Concentrator 5301 (Hambury, Germany)
at 30C. The desiccated gel pieces were rehydrated with 3 mL of
freshly prepared enzyme solution (20 ng/mL) containing sequencing
grade modiﬁed trypsin in 25mM ammonium bicarbonate and
incubated at 4C for 1 hour. To keep the gel wet overnight at 37C,
3 mL of 25mM ammonium bicarbonate was added. After 16 hours,
3 mL of solution in the tube was added to 2 mL of 100% acetonitrile
and 1% triﬂuoracetic acid (TFA) and then sonicated for 10 minutes.
Then, the supernatantwas recovered. The acetonitrile/acid stepwas
repeated, and the supernatants pooled. The peptide mixture was
prepared for matrix-assisted laser desorption/ionization time-of-
ﬂight mass spectrometry (MALDI-TOF/MS) analysis.
MALDI-TOF/MS analysis
Samples of freshly prepared matrix solution containing 1.5 mg/
mL of a-cyano-4-hydroxycinnamic acid (CHCA), 0.1% TFA, 80% ceric
ammonium nitrate (CAN), and 20% MilliQ water were prepared for
MALDI-TOF/MS analysis. The peptide calibration standard II
mixture allows calibrations (5  250 calibration points) and testing
of MALDI-TOF mass spectrometers in a mass range between
approximately 700 Da and 4000 Da. The standard calibration
mixture contains nine standard peptides: bradykinin 1e7, angio-
tensin II, angiotensin I, substance P, bombesin, renin substrate,
adrenocorticotropic hormone (ACTH) clip 1e17, ACTH clip 18e39,
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mixture and peptide mixture were spotted onto a freshly cleaned
anchor chip 600/384 sample plate and allowed to crystallize, then
the matrix solution was added to the sample plate and left to dry at
room temperature. Peptide mixtures were analyzed using a matrix-
assisted laser desorption tandem TOF mass spectrometer equipped
with a 50-Hz 332-nm N2 laser (Ultraﬂex II MALDI-TOF-TOF MS/MS,
Bruker Daltonics, Bremen, Germany). Peptide matching and protein
searches were performed automatically using MASCOT software
(Matrix Sciences, London, UK). Proteins with a MASCOT score 65
and a peptide sequence coverage 20% matched peptides were
considered as candidates for identiﬁcation. For peptide identiﬁca-
tion, monoisotopic masses and a mass tolerance of 150 ppm were
used. Only onemissed trypsin cleavagewas allowed. All extraneous
peaks, such as trypsin autodigests, matrix, and keratin peaks were
not considered for protein searches. The peptide masses were
compared with the theoretical peptide masses of all available
proteins from Homo sapiens using the SwissProt and National
Center for Biotechnology Information (NCBInr) databases. A p
value < 0.05 identiﬁed by the software was used as the criterion for
afﬁrmative protein identiﬁcation.
Validation of elevated serum proteins in proteomic display by
immunoassays
The serum levels of a1-antitrypsin, a1-microglobulin, clusterin,
and haptoglobin (Hp) of the control group (additional 41 pre-
eclamptic and 50 healthy pregnant women) were measured using
enzyme-linked immunoassay (ELISA) for validation. The serum
levels of a1-antitrypsin and Hp were measured by the BN system
(Dade Behring, Siemens Healthcare, Erlangen, Germany). The
serum levels of a1-microglobulin and clusterin were measured by
an ELISA kit (BioVendor Laboratory Medicine, Inc., Modrice, Czech
Republic).
Statistical analysis
Expressed as mean ± standard deviation, hematological pa-
rameters were compared between patient and control groups using
the paired Student t test. A p value of < 0.05 was considered sig-
niﬁcant. Statistical analyses for the study were performed using
SPSS 12.0 for Windows (SPSS Inc., Chicago, IL, USA).
Results
Demographic data between preeclampsia and normal pregnant
women
The preliminary results of analysis of demographic data are
shown in Table 1. The mean maternal age and gestational age (GA)
of the study participants in both groups were 33.2 ± 3.2 years
versus 33.1± 6.1years and 30.6± 1.3weeks versus 32.7± 2.8weeks,
respectively, showing no signiﬁcant difference. In the validation
group, the mean maternal age and GA were 31.6 ± 4.3 years versus
32.8 ± 5.0 years and 34.9 ± 4.3 weeks versus 34.3 ± 4.2 weeks,
respectively. However, pregnant women with preeclampsia had
signiﬁcantly higher mean systolic blood pressure
(180.7 ± 11.6 mmHg vs. 125 ± 9.4 mmHg in screened participants
and 172.2 ± 16.7 mmHg vs. 119.5 ± 9.9 mmHg in validated partic-
ipants) and diastolic blood pressure (112.3 ± 5.7 mmHg vs.
72.2 ± 9.7mmHg in screened participants and 107.5 ± 7.8 mmHg vs.
68.9 ± 10.42 mmHg in validated participants; p < 0.001), and lower
mean fetal birth weight (1620 ± 675.5 g vs. 3041.4 ± 99.5 g in
screened participants and 2012.4 ± 1035.6 g vs. 3187.4 ± 375.3 g in
validated participants; p < 0.005).Protein proﬁles of sera from screening group with preeclamptic and
healthy pregnant women
A representative serum protein proﬁle of a preeclampsia patient
was displayed by 2-DE and silver stain as shown in Figure 1; the
protein spots identiﬁed from silver stained gels were compared
using the Image Master 5.0 software. There were several protein
spots differentially showing upregulation and downregulation.
However, only 10 protein spots were found to bemore than twofold
upregulated in the sera of preeclampsia patients (Figure 1).
Identiﬁcation of differentially upregulated proteins
These 10 upregulated protein spots were trypsin-digested and
then submitted to MALDI-TOF-MS for protein identiﬁcation. With
the use of MASCOT search software for protein identiﬁcation, the
results showed that all 10 upregulated protein spots had the pep-
tide mass ﬁngerprints (PMF) matching up to four corresponding
proteins in the SwissProt (SWISS 2DPAGE) and NCBInr databases,
which were a1-antitrypsin, a1-microglobulin, clusterin, and Hp.
The details of the analytical results of these proteins are shown in
Table 2.
Immunoassay of an independent series of serum samples
Additional immunoassay was performed to compare the serum
levels of a1-antitrypsin, a1-microglobulin, clusterin, and Hp be-
tween the study groups of preeclampsia patients and normal
pregnant women. The concentrations of a1-antitrypsin, a1-
microglobulin, and clusterin increased linearly in standard serum
diluted between 1/2400 and 1/300. Samples were measured after
1000-fold dilution. Sera of 41 preeclampsia patients and 50 normal
pregnant women were measured and the levels of a1-antitrypsin,
a1-microglobulin, clusterin, and Hp in both groups are shown in
Figure 2. Mean serum levels of a1-antitrypsin, a1-microglobulin,
and clusterin in the preeclamptic group were signiﬁcantly higher
than those in the control group (a1-antitrypsin 295.95 ± 50.94 mg/
dL vs. 259.31 ± 33.90 mg/dL, p ¼ 0.02; a1-microglobulin
0.029 ± 0.004 mg/mL vs. 0.020 ± 0.004 mg/mL, p < 0.0001; clus-
terin 77.6 ± 16.15 mg/dL vs. 67.6 ± 15.87 mg/dL, p < 0.05). Mean
serum Hp levels were not signiﬁcantly different between groups
(83.32 ± 64.20 mg/dL vs. 89.11 ± 38.83 mg/dL, p ¼ 0.68).
Discussion
In the present study, proteomic analyses were performed to ﬁnd
that a1-antitrypsin, a1-microglobulin, and clusterin were candi-
date proteins associated with preeclampsia in pregnant women.
Although the underlying cause of preeclampsia remains unknown,
a commonly accepted theory is that the disease progresses in two
stages. First, an impaired cytotrophoblastic invasion of myometrial
segments leads to the spiral arteries narrowing and therefore the
blood supply to the fetus is restricted. Inadequate perfusion of the
placenta results in local ischemia and oxidative stress with for-
mation of free radicals and reactive oxygen species (ROS). All these
compounds are toxic because they can cause oxidative damage to
DNA, matrix molecules, cell membranes, and other tissue compo-
nents. The second stage is thematernal response to oxidative stress,
causing the wide spread of endothelial dysfunction which charac-
terizes preeclampsia [10].
Alpha 1-antitrypsin is an “acute-phase” protein with the pri-
mary function to protect tissues against the proteolytic enzymes
released after an inﬂammatory process [11]. As an “acute-phase”
protein, the plasma a1-antitrypsin concentration can increase in
response to stimuli such as infection or tissue trauma. Together
Table 1
Participant characteristics in the present study.
Screened participants pa Validated participants pa
Normal pregnant
women (n ¼ 8)
Severe preeclamptic
women (n ¼ 8)
Normal pregnant
women (n ¼ 50)
Severe preeclamptic
women (n ¼ 41)
Age (y) 33.2 ± 3.2 33.1 ± 6.1 NS 31.6 ± 4.3 32.8 ± 5.0 NS
GA (wk) 30.6 ± 1.3 32.7 ± 2.8 NS 34.9 ± 4.3 34.3 ± 4.2 NS
BW (g) 3041.4 ± 399.5 1620 ± 675.5 0.002 3187.4 ± 375.3 2012.4 ± 1035.6 0.004
SBPb (mmHg) 125 ± 9.4 180.7 ± 11.6 <0.001 119.5 ± 9.9 172.2 ± 16.7 <0.001
DBPb (mmHg) 72.2 ± 9.7 112.3 ± 5.7 <0.001 68.9 ± 10.42 107.5 ± 7.8 <0.001
Data are expressed as mean ± standard deviation.
BW ¼ birth weight; DBP ¼ diastolic blood pressure; GA ¼ gestational age; NS ¼ not signiﬁcant; SBP ¼ systolic blood pressure.
a For the difference between the preeclamptic and normal individuals, calculations were carried out by two-way analysis of variance.
b Data for SBP/DBP were collected upon the diagnosis of severe preeclampsia in the study group while in the control group the BP was measured soon after informed
consent.
Figure 1. Representative serum protein proﬁle patterns of normal and preeclamptic woman produced by two-dimensional gel electrophoresis and silver stain. The arrows indicate
spots with signiﬁcant differential expression, which were later identiﬁed to be a1-antitrypsin, a1-microglobulin, clusterin, and haptoglobin.
Table 2
Signiﬁcant differentially expressed proteins identiﬁed in the serum of preeclamptic women.
Spot no. NCBI entry Protein name pl/mass, kDa Sequence coverage, MS/MSMS,% MASCOT Score No. of sequenced peptides Functionsa
1 gi1942629 a1-antitrypsin 5.4/44.3 42/7 76 2 a, e, f, o
2 gi1942629 a1-antitrypsin 5.4/44.3 37/8 70 2 a, e, f, o
3 gi4826762 Haptoglobin 8.5/45.2 35/5 132 2 a
4 gi32891795 Clusterin 6.7/48.7 32/6 74 1 b, c, e
5 gi32891795 Clusterin 6.7/48.7 30/4 81 1 b, c, e
6 gi1942629 a1-antitrypsin 5.4/44.3 45/7 73 2 a, e, f, o
7 gi1942629 a1-antitrypsin 5.4/44.3 45/7 75 2 a, e, f, o
8 gi 55957384 a1-microglobulin 5.9/39.9 39/16 128 3 b, c, e
9 gi4826762 Haptoglobin 8.5/45.2 46/10 122 2 a
10 gi4826762 Haptoglobin 8.5/45.2 40/8 133 2 a
MS ¼ mass spectrometry; NCBI¼National Center for Biotechnology Information.
a a¼ acute phase protein; b¼ transport scavenger proteins; c¼ immunemodulation; e¼ protease inhibitor; f¼ coagulation; o¼ antiviral activity (based on the description
on http://harvester.embl.de).
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ceruloplasmin, a1-antitrypsin is classiﬁed as one of the
inﬂammation-sensitive plasma proteins (ISPs) that are used in
clinical practice to measure the degree of inﬂammation and to
differentiate between inﬂammatory diseases. Elevation of ISP levelswas also associated with an increase in incidence of cardiovascular
diseases [12,13]. Legge et al [14] showed that the serum levels of a1-
antitrypsin in the severe hypertension patients were signiﬁcantly
higher when compared with the normotensive patients. However,
the role of a1-antitrypsin in the pathogenesis of preeclampsia is
Figure 2. Immunoassays of four candidate proteins: a1-antitrypsin, a1-microglobulin, clusterin, and haptoglobin. The serum levels of (A) a1-antitrypsin, (B) a1-microglobulin, and
(C) clusterin were increased signiﬁcantly in preeclamptic women, whereas the serum levels of (D) haptoglobin were similar in both groups.
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antitrypsin levels increased as gestation progressed, however, the
degree of increment was more signiﬁcant in women with severe
preeclampsia [15]. Serum a1-antitrypsin levels were demonstrated
to be higher in women with severe preeclampsia similar to the
results in the current study, however, further investigation is
needed to evaluate whether this biomarker is feasible for the pre-
diction of preeclampsia for women in their ﬁrst trimester.
Human a1-microglobulin, a low-molecular-weight (26 kDa)
glycosylated protein in plasma and tissue, is synthesized by liver
cells and rapidly distributed via blood to the extravascular
compartment [16]. In normal physiologic conditions it is freely
ﬁltered in the kidneys and completely reabsorbed in the proximal
tubules. However, in the pathologic conditions such as pre-
eclampsia, the load of high-molecular-weight protein increases
which competes with reuptake of low-molecular-weight proteins
such as a1-microglobulin, resulting in the signiﬁcant leakage of this
protein to the urine [17]. These data support the idea that the
increased excretion of urinal a1-microglobulin in women with
preeclampsia is a sign of endothelial dysfunction. Recent reports
suggest that a1-microglobulin is involved in the defense against
oxidative tissue damage (oxidative stress) and therefore its
expression has been shown to be upregulated in response to ROS
[18,19]. Increased serum a1-microglobulin levels of women in their
ﬁrst trimesters are believed to be a sign of subsequent development
of preeclampsia [20]. Our results also demonstrated that the serum
a1-microglobulin level was signiﬁcantly higher in preeclampsia
patients, reﬂecting its biological role against oxidative stress.
Clusterin (apolipoprotein J) is a 75e80-kDa disulﬁde-linked
heterodimeric glycoprotein associated with apoptosis, oxidative
stress, hypoxia, cancers, and neurological disorders [21]. Because ofits biological characteristics, upregulation of clusterin expression
might be associated with preeclampsia. Watanabe et al [22] were
the ﬁrst to reveal elevated serum levels of clusterin in patients with
preeclampsia. Later, an immunohistochemical study also concluded
that overexpression of clusterin in placental tissues might play an
important role in the pathogenesis of preeclampsia [23]. We
conﬁrmed the signiﬁcance of clusterin in preeclampsia bymeans of
a proteomics technique and serum level analysis. However, the
predictive role of serum clusterin levels for the women in their ﬁrst
trimester would actually be the most interesting part for future
studies.
Hp is one of the ﬁve ISPs mentioned above; any inﬂammatory
process may increase the plasma levels of Hp. In blood plasma, Hp
binds to free hemoglobin (Hb) which is released from erythrocytes
owing to hemolysis to counteract its oxidative activity and thus
protects against cell damage [24,25]. The HpeHb complex is then
removed by the reticuloendothelial system. This causes a decline in
serum Hp levels. Owing to a genetic polymorphism, there are three
different Hp genotypes in humans [25]. Previous studies showed
that Hp with different genotypes would exhibit quite different
biological activities due to their different binding afﬁnities to Hb,
reﬂecting the inconsistent results regarding the association be-
tween serum Hp levels and preeclampsia [26e28]. For example,
Arinola et al [29] found that the serum Hp level was signiﬁcantly
raised in preeclampsia patients when compared with women
having normal pregnancy. By contrast, Olsson et al [30] reported
that the serum Hp concentrations of preeclampsia patients were
signiﬁcantly depressed. However, no signiﬁcant difference of serum
Hp levels was found between groups in our study.
In conclusion, we used a proteomic tool to identify three pro-
teins: a1-antitrypsin, a1-microglobulin, and clusterin, which were
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related to oxidative stress and inﬂammation, suggesting that
oxidative stress, hypoxia, and inﬂammation are important events
involved in the natural course of preeclampsia. Further studies are
warranted to investigate these biomarkers in maternal serum alone
or in combination as ﬁrst-trimester predictors for this disease.
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